arixtra sales disappoint, page-2

Arixtra sales have doubled year on year, full year looks like being US$200M, compared to $100M in 06.

Quarterly sales fluctuate as the wholesale distributors hold of buying until prior to the new year price rises, this is a given in wholesale distribution, hence the December quarter sales will be bigger.

The company is expecting approval from the FDA for ACS indication in the new year which will be a major filip for Arixtra.

The recent price drop is more to do with an overhang of stock as Mark Rowsthorn has been reducing his holding, he is now below 5%, with these sales supressing the share price. Once this overhang is gone the selling pressure will be released, similar to Accrux, and put trading back on an even keel allowing the price to move north.

The story still remains intact.